Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$1.09 - $1.67 $2,180 - $3,340
-2,000 Reduced 90.91%
200 $0
Q2 2022

Aug 04, 2022

SELL
$1.13 - $3.69 $2,033 - $6,642
-1,800 Reduced 45.0%
2,200 $0
Q1 2022

Apr 14, 2022

SELL
$2.85 - $3.73 $4,560 - $5,968
-1,600 Reduced 28.57%
4,000 $0
Q2 2021

Jul 19, 2021

SELL
$4.26 - $6.5 $42,600 - $65,000
-10,000 Reduced 64.1%
5,600 $0
Q1 2021

Apr 26, 2021

SELL
$5.03 - $8.8 $250,997 - $439,120
-49,900 Reduced 76.18%
15,600 $5,000
Q4 2020

Jan 21, 2021

SELL
$4.04 - $5.31 $11,716 - $15,398
-2,900 Reduced 4.24%
65,500 $5,000
Q3 2020

Oct 27, 2020

SELL
$3.64 - $7.76 $46,592 - $99,328
-12,800 Reduced 15.76%
68,400 $6,000
Q2 2020

Jul 22, 2020

SELL
$4.78 - $8.26 $756,674 - $1.31 Million
-158,300 Reduced 66.1%
81,200 $45,000
Q1 2020

May 07, 2020

BUY
$4.0 - $21.53 $600,400 - $3.23 Million
150,100 Added 167.9%
239,500 $9,000
Q4 2019

Feb 06, 2020

SELL
$13.94 - $24.12 $2,788 - $4,824
-200 Reduced 0.22%
89,400 $195,000
Q3 2019

Oct 28, 2019

BUY
$13.89 - $23.16 $190,293 - $317,292
13,700 Added 18.05%
89,600 $91,000
Q2 2019

Aug 09, 2019

SELL
$16.27 - $20.51 $81,350 - $102,550
-5,000 Reduced 6.18%
75,900 $79,000
Q1 2019

May 10, 2019

SELL
$12.61 - $22.33 $1.61 Million - $2.85 Million
-127,700 Reduced 61.22%
80,900 $148,000
Q4 2018

Feb 05, 2019

SELL
$12.41 - $22.98 $43,435 - $80,430
-3,500 Reduced 1.65%
208,600 $1.03 Million
Q3 2018

Nov 07, 2018

BUY
$2.45 - $16.27 $490,735 - $3.26 Million
200,300 Added 1697.46%
212,100 $1.64 Million
Q2 2018

Aug 10, 2018

BUY
$2.68 - $3.48 $23,584 - $30,624
8,800 Added 293.33%
11,800 $13,000
Q4 2017

Jan 17, 2018

SELL
$3.06 - $4.09 $1,530 - $2,045
-500 Reduced 14.29%
3,000 $4,000
Q3 2017

Oct 17, 2017

BUY
$3.03 - $3.72 $10,605 - $13,020
3,500
3,500 $3,000

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $185M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.